Please login to the form below

Not currently logged in
Email:
Password:

Ophthotech

This page shows the latest Ophthotech news and features for those working in and with pharma, biotech and healthcare.

Novartis' AMD drug pegpleranib fails phase III programme

Novartis' AMD drug pegpleranib fails phase III programme

The results of two phase III trials of pegpleranib - an anti-PDGF aptamer originally developed by OphthoTech - showed that adding it to therapy with Lucentis (ranibizumab) in patients with the neovascular ... While a minor blow to Novartis as well as

Latest news

  • Novartis licenses Ophthotech eye drug in $1bn deal Novartis licenses Ophthotech eye drug in $1bn deal

    s Avastin (bevacizumab), so the Ophthotech deal gives Novartis an alternative therapeutic option as well as the possibility of developing a combination treatment. ... Ophthotech has retained rights to the drug in the US and will also earn royalties on

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Acquisition of voucher. 125. AVEO Oncology / Ophthotech Corporation. VEGF tyrosine kinase inhibitor tivozanib.

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    1, 400. Ophthotech / Novartis. Commercialisation. 1. and co-development licence. Fovista (start p3) for treatment of wet age-related macular degeneration.

  • Pharma deals during May 2014 Pharma deals during May 2014

    Top of the list was Ophthotech's commercialisation and co-development agreement with Novartis for Fovista, an anti-PDGF agent, in phase 3 for wet age-related macular degeneration (AMD).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics